News Summary

Eli Lilly’s daily anti-obesity pill, orforglipron, has shown promising results in a Phase 3 trial, demonstrating effectiveness similar to popular injectable GLP-1 drugs like Ozempic. The trial, which included 559 patients with type 2 diabetes, tested three doses of orforglipron, showing significant reductions in blood sugar and body weight, particularly at the higher doses. The highest dose led to an average weight loss of 7.9 percent, comparable to injectable alternatives. Orforglipron offers potential advantages such as easier storage and transportation and does not require cold-chain logistics, unlike injectable GLP-1 drugs. Eli Lilly plans to seek regulatory approval for orforglipron for weight management by the end of this year, with further studies ongoing to explore long-term impacts on obesity and diabetes management.